Technology area: Biotechnology & Pharmaceuticals
16 pending office actions • 14 art units • 16 examiners • 0 of 16 (0%) have an AI response strategy ready • 13 patents granted in the last 365 days
Temple University has 16 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 16 examiners and 14 art units, indicating broad examination coverage with nearly every matter receiving a distinct examiner assignment.
OGLES, MATTHEW ERIC is the busiest examiner, with 1 pending action. The workload is therefore dispersed rather than concentrated in one examiner’s docket.
The portfolio calls for rigorous matter-level tracking and coordination across art units. Counsel can use shared technical and claim resources where appropriate, but each response should be tailored to its examiner and prosecution history. Centralized deadline control is particularly important because no single examiner relationship provides a practical substitute for portfolio-wide oversight.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (19%) |
| §103 only | 2 (12%) |
| §112 only | 2 (12%) |
| Double-patenting + other | 2 (12%) |
| Multi-statute (no §101) | 7 (44%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OGLES, MATTHEW ERIC | 1 | 50.0% | +58.4% |
| ALLEY, GENEVIEVE S | 1 | 60.5% | +48.3% |
| ROBINSON, MIKHAIL O'DONNEL | 1 | 58.3% | +43.1% |
| PYLA, EVELYN Y | 1 | 55.8% | +47.1% |
| CABRAL, ROBERT S | 1 | 62.8% | +32.3% |
| HAVLIN, ROBERT H | 1 | 51.3% | +28.3% |
| SZNAIDMAN, MARCOS L | 1 | 37.4% | +16.1% |
| PIHONAK, SARAH | 1 | 61.4% | +42.4% |
| MARVICH, MARIA | 1 | 55.0% | +28.0% |
| LEITH, NANCY J | 1 | 74.7% | +44.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17938209 | BAG3 AS A TARGET FOR THERAPY OF HEART FAILURE | POLIAKOVA-GEORGAN, EKATERINA | 84d overdue |
| 18040515 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE RELEASE SYNDROME | PIHONAK, SARAH | 45d overdue |
| 18329957 | METHODS OF TREATING DISEASES AND DISORDERS ASSOCIATED WITH CALCIUM ION SIGNALING | SZNAIDMAN, MARCOS L | 9d overdue |
| 18300468 | PHARMACOLOGIC APPROACH FOR SUPPRESSION OF CORONAVIRUSES | CHO, DAVID H | 63d |
| 19014404 | SYSTEM AND METHOD FOR ASSESSMENT AND REHABILITATION OF BALANCE IMPAIRMENT USING VIRTUAL REALITY | OGLES, MATTHEW ERIC | — |
| 18793238 | METHODS AND COMPOSITIONS FOR TREATING LIVER DISEASE | ROBINSON, MIKHAIL O'DONNEL | — |
| 18426838 | Microencapsulation of Active Agents | CABRAL, ROBERT S | — |
| 18577107 | OLIGONUCLEOTIDES AND VIRAL UNTRANSLATED REGION (UTR) FOR INCREASING EXPRESSION OF TARGET GENES AND PROTEINS | PERSONS, JENNA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18040515 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE RELEASE SYNDROME | PIHONAK, SARAH | 45d overdue |
| 18329957 | METHODS OF TREATING DISEASES AND DISORDERS ASSOCIATED WITH CALCIUM ION SIGNALING | SZNAIDMAN, MARCOS L | 9d overdue |
| 18609070 | Use of Short Chain Fatty Acids in Cancer Prevention | PYLA, EVELYN Y | 2d overdue |
| 19014404 | SYSTEM AND METHOD FOR ASSESSMENT AND REHABILITATION OF BALANCE IMPAIRMENT USING VIRTUAL REALITY | OGLES, MATTHEW ERIC | — |
| 18975545 | Use of short chain fatty acids for the treatment and prevention of diseases and disorders | ALLEY, GENEVIEVE S | — |
| 18793238 | METHODS AND COMPOSITIONS FOR TREATING LIVER DISEASE | ROBINSON, MIKHAIL O'DONNEL | — |
| 18426838 | Microencapsulation of Active Agents | CABRAL, ROBERT S | — |
| 18413255 | FUNCTIONALIZED N,N-DIALKYLAMINO PHENYL ETHERS AND THEIR METHOD OF USE | HAVLIN, ROBERT H | — |
| Art Unit | Apps |
|---|---|
| 1627 | 2 |
| 1637 | 2 |
| 3791 | 1 |
| 1617 | 1 |
| 1633 | 1 |
| 1614 | 1 |
| 1626 | 1 |
| 1628 | 1 |
| 1634 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19014404 | SYSTEM AND METHOD FOR ASSESSMENT AND REHABILITATION OF BALANCE IMPAIRMENT USING VIRTUAL REALITY | OGLES, MATTHEW ERIC | 3791 | §103§112 | Non-Final OA | — | Pending | Jan 09, 2025 |
| 18975545 | Use of short chain fatty acids for the treatment and prevention of diseases and disorders | ALLEY, GENEVIEVE S | 1617 | §103DP | Non-Final OA | — | Pending | Dec 10, 2024 |
| 18793238 | METHODS AND COMPOSITIONS FOR TREATING LIVER DISEASE | ROBINSON, MIKHAIL O'DONNEL | 1627 | §102§103 | Non-Final OA | — | Pending | Aug 02, 2024 |
| 18609070 | Use of Short Chain Fatty Acids in Cancer Prevention | PYLA, EVELYN Y | 1633 | §103 | Final Rejection | 2d overdue | Pending | Mar 19, 2024 |
| 18426838 | Microencapsulation of Active Agents | CABRAL, ROBERT S | 1614 | §102§103 | Non-Final OA | — | Pending | Jan 30, 2024 |
| 18413255 | FUNCTIONALIZED N,N-DIALKYLAMINO PHENYL ETHERS AND THEIR METHOD OF USE | HAVLIN, ROBERT H | 1626 | §102§112DP | Non-Final OA | — | Pending | Jan 16, 2024 |
| 18329957 | METHODS OF TREATING DISEASES AND DISORDERS ASSOCIATED WITH CALCIUM ION SIGNALING | SZNAIDMAN, MARCOS L | 1628 | §103§112 | Final Rejection | 9d overdue | Pending | Jun 06, 2023 |
| 18040515 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE RELEASE SYNDROME | PIHONAK, SARAH | 1627 | §103§112 | Final Rejection | 45d overdue | Pending | Feb 03, 2023 |
| 17904229 | LINKING AMINO ACID SEQUENCES, MANUFACTURING METHOD THEREOF, AND USE THEREOF | MARVICH, MARIA | 1634 | §103 | Non-Final OA | — | Pending | Aug 15, 2022 |
| 17832457 | METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION | LEITH, NANCY J | 1636 | §112Other | Final Rejection | — | Pending | Jun 03, 2022 |
| 16484953 | Methods and Compositions for Treating Neurodegeneration and Fibrosis | CHERNYSHEV, OLGA N | 1675 | §112 | Final Rejection | — | Pending | Aug 09, 2019 |
| 18577107 | OLIGONUCLEOTIDES AND VIRAL UNTRANSLATED REGION (UTR) FOR INCREASING EXPRESSION OF TARGET GENES AND PROTEINS | PERSONS, JENNA L | 1637 | §101§102§112 | Non-Final OA | — | Pending | Jan 05, 2024 |
| 18553584 | IMMUNE MODULATORY PARACRINE ACTING CELLS (IMPACS) | NGUYEN, NGHI V | 1653 | §101§103§112 | Non-Final OA | — | Pending | Oct 02, 2023 |
| 18300468 | PHARMACOLOGIC APPROACH FOR SUPPRESSION OF CORONAVIRUSES | CHO, DAVID H | 1693 | §103§112 | Final Rejection | 63d | Pending | Apr 14, 2023 |
| 17837352 | RNA GUIDED ERADICATION OF VARICELLA ZOSTER VIRUS | SHIN, DANA H | 1635 | §103§112 | Non-Final OA | — | Pending | Jun 10, 2022 |
| 17938209 | BAG3 AS A TARGET FOR THERAPY OF HEART FAILURE | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §101DP | Final Rejection | 84d overdue | Pending | Oct 05, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTemple University has 16 pending office actions as of October 2026, spread across 14 art units and 16 examiners.
Matthew Eric Ogles has the most, with 1 of Temple University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
